UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section  
13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20,  
2025 Johnson & Johnson (Exact name of registrant as specified in its charter)                                      
                                                                                 
  New Jersey                      1-3215                     22-1024240          
  (State or Other Jurisdiction    -Commission File Number    -IRS Employer       
  of Incorporation)                                          Identification No.  
                                                                                 
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of Principal Executive Offices) Registrant’s 
telephone number, including area code: 732- 524-0400 Check the appropriate box below if the Form 8-Kfiling is      
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
                                                                                            
  ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
                                                                                            
                                                                                             
  ☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
                                                                                             
                                                                                                             
  ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
                                                                                                             
                                                                                                             
  ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
                                                                                                             
Securities registered pursuant to Section 12(b) of the Act:                                                        
                                                                                            
  Title of each class               Trading      Name of each exchange on which registered  
                                    Symbol(s)                                               
  Common Stock, Par Value $1.00     JNJ          New York Stock Exchange                    
  1.150% Notes Due November 2028    JNJ28        New York Stock Exchange                    
  3.200% Notes Due June 2032        JNJ32        New York Stock Exchange                    
  1.650% Notes Due May 2035         JNJ35        New York Stock Exchange                    
  3.350% Notes Due June 2036        JNJ36A       New York Stock Exchange                    
  3.550% Notes Due June 2044        JNJ44        New York Stock Exchange                    
                                                                                            
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the          
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§240.12b-2of
this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant   
has elected not to use the extended transition period for complying with any new or revised financial accounting   
standards provided pursuant to Section 13(a) of the Exchange Act. ☐                                                
                           
  Item 8.01  Other Events  
                           
On February 20, 2025, Johnson & Johnson (the “Company”) completed the previously announced public offerings of the 
following:                                                                                                         
                                                                                             
  (1)  $750,000,000 aggregate principal amount of 4.500% Notes due 2027 (the “2027 Notes”);  
                                                                                             
                                                                                             
  (2)  $750,000,000 aggregate principal amount of 4.550% Notes due 2028 (the “2028 Notes”);  
                                                                                             
                                                                                               
  (3)  $1,000,000,000 aggregate principal amount of 4.700% Notes due 2030 (the “2030 Notes”);  
                                                                                               
                                                                                                   
  (4)  $1,250,000,000 aggregate principal amount of 4.850% Notes due 2032 (the “2032 Notes”); and  
                                                                                                   
                                                                                                                   
  (5)  $1,250,000,000 aggregate principal amount of 5.000% Notes due 2035 (the “2035 Notes” and, together with     
       the 2027 Notes, the 2028 Notes, the 2030 Notes and the 2032 Notes, the “Notes”);                            
                                                                                                                   
under the Company’s Registration Statement on Form S-3,Reg. No. 333-269836. In connection with the offering of the 
Notes, the Company entered into an underwriting agreement on February 18, 2025, which is filed as Exhibit 1.1      
hereto (the “Underwriting Agreement”), with Citigroup Global Markets Inc., BofA Securities, Inc. and J.P. Morgan   
Securities LLC, as representatives of the several Underwriters named therein (the “Underwriters”), pursuant to     
which the Company agreed to issue and sell the Notes to the Underwriters. The Underwriting Agreement incorporates  
the Underwriting Agreement Standard Provisions (Debt), dated February 18, 2025, which is filed as Exhibit 1.2      
hereto.                                                                                                            
                                                 
  Item 9.01  Financial Statements and Exhibits.  
                                                 
(d) Exhibits.                                                                                                      
                                                                                                                   
             Description                                                                                           
  Exhibit    Underwriting Agreement, dated February 18, 2025, among Johnson & Johnson and Citigroup Global         
  No.        Markets Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC, as representatives of the        
  1.1        several Underwriters named therein.                                                                   
  1.2        Underwriting Agreement Standard Provisions (Debt) dated February 18, 2025.                            
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
  4.1        Company Order establishing the terms of the Notes.                                                    
  4.2        Form of 4.500% Notes due 2027.                                                                        
  4.3        Form of 4.550% Notes due 2028.                                                                        
  4.4        Form of 4.700% Notes due 2030.                                                                        
  4.5        Form of 4.850% Notes due 2032.                                                                        
  4.6        Form of 5.000% Notes due 2035.                                                                        
  5.1        Opinion of Weil, Gotshal & Manges LLP.                                                                
  5.2        Opinion of Troutman Pepper Locke LLP.                                                                 
  23.1       Consent of Weil, Gotshal & Manges LLP (included in Exhibit 5.1 of this Current Report on Form 8-K).   
  23.2       Consent of Troutman Pepper Locke LLP (included in Exhibit 5.2 of this Current Report on Form 8-K).    
  104        The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.                          
                                                                                                                   
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.                                     
                                                                      
                                    JOHNSON & JOHNSON                 
                                    (Registrant)                      
  Date: February 20, 2025    By:    /s/ Marc Larkins                  
 ──────────────────────────────────────────────────────────────────── 
                                    Marc Larkins Corporate Secretary  
                                                                      
